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Abstract
Multiple myeloma (MM) is a plasma cell disorder primarily involving bone marrow. Extramedullary involvement 
is less common, with central nervous system (CNS) myelomatosis being a rare entity and such presentation carries 
extremely dismal prognosis. We present case of a 40 years old male with MM who was initially treated with 6 cycles 
of Cyclophosphamide, Thalidomide and Dexamethasone resulting in complete response. 2 years later he presented 
with CNS myelomatosis and scrotal involvement and was initially treated with Bortezomib and dexamethasone, cranial 
irradiation and intrathecal Methorexate, Cytarabine, Hydrocortisone (TRIO IT), along with radical orchiectomy and 
testicular radiation during the course of treatment. However, after initial response his disease showed clinical and 
radiological progression after 4 months of therapy. He was switched to high dose Methotrexate (HD-MTX) with TRIO-
IT and later Lenalidamide and dexamethasone (Len/dex) was added to the above regimen. He continued to show good 
clinical response but his cytology remained persistently positive, therefore, HD-MTX was discontinued in the later 
course of treatment. Subsequently he was started on best supportive care only, when his neurological status deteriorated 
further. He survived almost 9 months after a diagnosis of CNS myelomatosis. Patients with multiple myeloma, presenting 
with neurological symptoms should always be investigated for the possibility of CNS MM. CNS relapse is a fatal disease 
with poor prognosis. Recommended treatment must include a systemic anti-MM regimen that crosses the BBB (ideally 
Immunomodulatory drugs (IMiDs) IMiDs-dexamethasone based therapy), CNS irradiation and intrathecal chemotherapy.
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Introduction
Multiple myeloma (MM) is a clonal disorder of plasma 
cells, mainly involving the bone marrow.[1] Extramedullary 
involvement of MM is seen in approximately 7% of the 
patients.[2] Central nervous system (CNS) involvement in 
MM is uncommon. Amongst its possible presentations, 
leptomeningeal dissemination of MM causing myelomatous 
meningitis (MyM), also termed CNS–myelomatosis, is one 
of the rarest complications of MM[3] with only a handful 
of reported cases and is characterised by the presence of 
neoplastic plasma cells in the cerebrospinal fluid (CSF). 
The incidence is reported to be approximately 1%[4] of MM 
patients with the median overall survival of <6 months.[5] 
Treatment of MyM is seldom curative and essentially 
palliative, with attempted preservation of neurologic 
function.[6] We present a case of treated MM who presented 
with isolated CNS relapse in the form of leptomeningeal 
disease after 2 years of achieving complete response (CR).
Case Report
A 40-year-old gentleman was diagnosed in 2012 with 
MM after a left humeral pathological fracture with tissue 
biopsy positive for plasma cell disorder, International 
Scoring System-II (marrow plasmacytosis 20%, M protein 
28.7 g/dl in gamma region, urine protein electrophoresis 
negative, beta 2 microglobulin 4 mg/dL and disseminated 
lytic lesions). Baseline whole spine imaging revealed 
multilevel osseous involvement with a significant 
compression fracture of the L5 vertebral body without 
spinal cord compromise at any level [Figures 1 and 2].
The patient completed 6 cycles of cyclophosphamide weekly, 
thalidomide once daily and dexamethasone (Dex) days 1–4, 
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9–12 (Cyclophosphamide, thalidomide, and dexamethasone) 
every 4 weeks and Zoledronic acid every 4 weeks and achieved 
CR in September 2012. Upfront high-dose therapy and 
autologous stem cell transplant were suggested to the patient, 
but he opted to be kept on surveillance only. In the meantime, 
the patient continued to receive monthly pamidronate.
In September 2014, the patient presented to the 
emergency room with a history of fall, a pathological 
fracture of the right humerus, dizziness, poor oral intake 
and altered sensorium. Magnetic resonance (MR) brain 
revealed diffuse leptomeningeal enhancement with mild 
communicating hydrocephalus concerning for infectious, 
inflammatory or MyM [Figure 3]. CSF revealed high 
protein (151 mg/dl), LDH and normal glucose. CSF 
cytology was positive for atypical plasma cells. His repeat 
bone marrow biopsy and blood workup at that point 
did not show any evidence of systemic disease. Flow 
cytometry showed approximately 96% of total cellular 
events characterised as CD45+/-, CD38++ and CD138+, 
confirming isolated CNS involvement by MM.
Figure 4: Transverse and longitudinal ultrasound image of the 
right testis shows enlargement and heterogonous parenchymal 
echotexture with hypoechoic lesions (arrow)
Figure 3: (a) AP projection of the right humerus shows an 
oblique complete fracture involving the proximal diaphysis 
with slight overriding of fracture fragments and displacement. 
(b) Coronal post-contrast magnetic resonance imaging of 
brain reveals diffuse supra- and infra-tentorial leptomeningeal 
enhancement with mild ventriculomegaly
ba
Figure 2: (a) T2-weighted sagittal magnetic resonance imaging 
(MRI) of lumbar spine shows T2 hyperintense well-defined 
lesion in L3 vertebral body and compression fracture of L5 
vertebral body. (b) Axial T2-weighted image shows bilateral 
sacral disease involvement. (c) Sagittal T2-weighted MRI of 
thoracic spine demonstrates T2 hyperintense lesions of similar 
morphology in thoracic spine and manubrium sterni
c
ba
Figure 1: (a) Frontal projection of the left humerus shows 
internal intramedullary nail fixation of distal diaphyseal fracture 
background lytic lesion with endosteal scalloping. (b) Lateral 
projection of skull shows punched-out lytic lesions. (c) Lateral 
lumbar radiograph demonstrates that wedge compression fracture 
of L5 vertebral body is noted with background osteopenia
c
ba
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Therefore, the patient was started on methotrexate, 
cytarabine and hydrocortisone given intrathecally, 
(TRIO-IT), and received cranial irradiation followed by 
bortezomib on days 1, 4, 8 and 11 and Dex on days 1–4 
(Bordex) every 3 weeks. He showed clinical improvement 
in his higher mental function after 2 weeks of therapy. 
The patient was subsequently noticed to have right 
testicular swelling [Figure 4] and right radical orchiectomy 
was performed with myelomatous involvement on 
histopathology. Later on, palliative radiotherapy to 
testicular area and humerus was offered as well. Clinical, 
cytological and radiological evaluation after 2 cycles of 
Bordex showed partial response.
In December 2014, clinical, cytological and radiological 
CNS disease progression was noted [Figure 5]. As a 
consequence, high-dose methotrexate every 3 weeks along 
with TRIO-IT was started. Lenalidomide (Len) was added 
to above regimen in view of disease progression. After 
completing 3 cycles of high-dose methotrexate and 1 cycle 
of Len and Dex, good clinical response was noted; however, 
CSF cytology was still positive and computed tomography 
showed persistent meningeal enhancement [Figure 6]. 
Therapy apart from TRIO-IT was stopped. In April 2015, he 
developed deterioration in neurological status and showed 
persistently positive cytology for atypical plasma cells. The 
patient was deemed to have refractory disease, and hence, 
active oncological treatment was withheld and was kept 
on best supportive care. The patient passed away almost 9 
months after CNS disease relapse.
Discussion
Leptomeningeal myelomatous involvement is very 
rare. The clinical presentations of CNS MM can be 
variable and can range from impaired cognition, 
headache, vomiting drowsiness, confusion, limb 
weakness, cranial nerve palsies, seizures and urinary 
incontinence.[6] The differential diagnosis of such a 
clinical presentation in MM includes hypercalcemia, 
hyperviscosity, spinal cord compression, CNS 
infection and peripheral neuropathy associated with 
immune-modulatory agents, amyloid deposition[6] and, 
rarely, POEMS syndrome.
The recommended workup for patients should include 
brain imaging, particularly MR imaging (MRI) brain, 
CSF analysis and complete metabolic screening to 
rule out differential diagnoses as mentioned above. 
Clonal characterisation of the atypical cells by cytology 
and flow cytometry is required. Protein measurement 
including intrathecal M-component by electrophoresis 
and immune fixation is also helpful to reach a diagnosis. 
Fluorescent in situ hybridisation testing for evaluation of 
the cytogenetic abnormalities should be performed, where 
available. For those cases, where MRI is suggestive of CNS 
involvement and CSF analysis including flow cytometry is 
inconclusive, surgical biopsy should be considered.
Figure 6: Contrast-enhanced computed tomography scan of the 
brain shows persistent meningeal enhancement along the basilar 
cisterns (a) with the right-sided subdural effusion causing subtle 
mass effect on the ipsilateral cerebral hemisphere (b)
ba
Figure 5: (a and b) T2 and post-contrast T1-weighted sagittal 
magnetic resonance imaging of lumbar spine shows interval 
decrease in the T2 high signal lesion in L3 vertebral body lesion. 
However, interval development of leptomeningeal enhancement 
along the spinal cord is suggestive of progressive meningeal 
myelomatous disease. (c) T1 post-contrast coronal images 
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Since CNS involvement by MM is rarely seen, there are 
no consensus guidelines on the management.[7] A study 
done by Usmani et al. has also highlighted an unmet 
need in this subset of patients with high risk, relapsed 
or refractory MM.[8] Therapy of CNS extramedullary 
myeloma (EMM) is difficult, needs both systemic and 
CNS-specific therapy. Systemic therapy for CNS EMM 
should include drugs that may cross the blood–brain 
barrier (BBB). Durable responses have been reported using 
thalidomide.[9] Pomalidomide has demonstrated a good 
penetration of the BBB and has shown efficacy in treating 
disease with CNS manifestations.[10,11] Bendamustine can 
be used as well. Recommended treatment must include a 
systemic anti-MM regimen that crosses the BBB (ideally 
an IMiD-dexamethasone-based therapy), CNS irradiation 
and intrathecal chemotherapy.[5]
There is a need for prospective trials to establish clear 
guidelines about the management of this disease; however, 
this may be relatively difficult due to a small number of 
patients presenting with this complication.
Conclusion
Patients with MM, presenting with neurological 
symptoms, should always be investigated for the 
possibility of CNS MM. CNS relapse is a fatal disease with 
poor prognosis. Recommended treatment must include a 
systemic anti-MM regimen that crosses the BBB (ideally 
an IMiD-dexamethasone-based therapy), CNS irradiation 
and intrathecal chemotherapy.
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